Literature DB >> 18071651

Salmon calcitonin: a review of current and future therapeutic indications.

C H Chesnut1, M Azria, S Silverman, M Engelhardt, M Olson, L Mindeholm.   

Abstract

Salmon calcitonin, available as a therapeutic agent for more than 30 years, demonstrates clinical utility in the treatment of such metabolic bone diseases as osteoporosis and Paget's disease, and potentially in the treatment of osteoarthritis. This review considers the physiology and pharmacology of salmon calcitonin, the evidence based research demonstrating efficacy and safety of this medication in postmenopausal osteoporosis with potentially an effect on bone quality to explain its abilities to reduce the risk of spine fracture, the development of an oral salmon calcitonin preparation, and the therapeutic rationale for this preparation's chondroprotective effect in osteoarthritis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18071651     DOI: 10.1007/s00198-007-0490-1

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  101 in total

Review 1.  Is bone mineral density predictive of fracture risk reduction?

Authors:  Charles A Cefalu
Journal:  Curr Med Res Opin       Date:  2004-03       Impact factor: 2.580

Review 2.  Rationale for the potential use of calcitonin in osteoarthritis.

Authors:  D H Manicourt; J P Devogelaer; M Azria; S Silverman
Journal:  J Musculoskelet Neuronal Interact       Date:  2005 Jul-Sep       Impact factor: 2.041

3.  A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.

Authors:  C H Chesnut; S Silverman; K Andriano; H Genant; A Gimona; S Harris; D Kiel; M LeBoff; M Maricic; P Miller; C Moniz; M Peacock; P Richardson; N Watts; D Baylink
Journal:  Am J Med       Date:  2000-09       Impact factor: 4.965

4.  Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study.

Authors:  G F Mazzuoli; M Passeri; C Gennari; S Minisola; R Antonelli; C Valtorta; E Palummeri; G F Cervellin; S Gonnelli; G Francini
Journal:  Calcif Tissue Int       Date:  1986-01       Impact factor: 4.333

5.  Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospective double-blind, randomized, placebo-controlled clinical study.

Authors:  G P Lyritis; G V Ioannidis; T Karachalios; N Roidis; E Kataxaki; N Papaioannou; J Kaloudis; A Galanos
Journal:  Clin J Pain       Date:  1999-12       Impact factor: 3.442

6.  Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis.

Authors:  Yu Z Bagger; László B Tankó; Peter Alexandersen; Morten A Karsdal; Melvin Olson; Linda Mindeholm; Moïse Azria; Claus Christiansen
Journal:  Bone       Date:  2005-09       Impact factor: 4.398

7.  25 years of salmon calcitonin: from synthesis to therapeutic use.

Authors:  M Azria; D H Copp; J M Zanelli
Journal:  Calcif Tissue Int       Date:  1995-12       Impact factor: 4.333

8.  Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study.

Authors:  G P Lyritis; I Paspati; T Karachalios; D Ioakimidis; G Skarantavos; P G Lyritis
Journal:  Acta Orthop Scand Suppl       Date:  1997-10

9.  Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study.

Authors:  Charles H Chesnut; Sharmilla Majumdar; David C Newitt; Andrew Shields; Jan Van Pelt; Ellen Laschansky; Moise Azria; Audrey Kriegman; Melvin Olson; Erik F Eriksen; Linda Mindeholm
Journal:  J Bone Miner Res       Date:  2005-04-27       Impact factor: 6.741

10.  Paget's disease of bone: experiences with 100 patients treated with salmon calcitonin.

Authors:  H S Grunstein; P Clifton-Bligh; S Posen
Journal:  Med J Aust       Date:  1981-09-19       Impact factor: 7.738

View more
  40 in total

1.  Efficacy and harms of nasal calcitonin in improving bone density in young patients with inflammatory bowel disease: a randomized, placebo-controlled, double-blind trial.

Authors:  Helen M Pappa; Tracee M Saslowsky; Rajna Filip-Dhima; Diane DiFabio; Hajar Hassani Lahsinoui; Apurva Akkad; Richard J Grand; Catherine M Gordon
Journal:  Am J Gastroenterol       Date:  2011-04-26       Impact factor: 10.864

2.  Calcitonin has a vasopressin-like effect on aquaporin-2 trafficking and urinary concentration.

Authors:  Richard Bouley; Hua A J Lu; Paula Nunes; Nicolas Da Silva; Margaret McLaughlin; Ying Chen; Dennis Brown
Journal:  J Am Soc Nephrol       Date:  2010-11-11       Impact factor: 10.121

3.  Mining MEDLINE for the treatment of osteoporosis.

Authors:  Pinar Yildirim; Cinar Ceken; Reza Hassanpour; Sadik Esmelioglu; Mehmet Resit Tolun
Journal:  J Med Syst       Date:  2011-04-15       Impact factor: 4.460

4.  N-Glycosylation of Asparagine 130 in the Extracellular Domain of the Human Calcitonin Receptor Significantly Increases Peptide Hormone Affinity.

Authors:  Sang-Min Lee; Jason M Booe; Joseph J Gingell; Virginie Sjoelund; Debbie L Hay; Augen A Pioszak
Journal:  Biochemistry       Date:  2017-06-26       Impact factor: 3.162

5.  Growth-incompetent monomers of human calcitonin lead to a noncanonical direct relationship between peptide concentration and aggregation lag time.

Authors:  Kian Kamgar-Parsi; Liu Hong; Akira Naito; Charles L Brooks; Ayyalusamy Ramamoorthy
Journal:  J Biol Chem       Date:  2017-07-24       Impact factor: 5.157

6.  Nasal salmon calcitonin blunts bone microstructure alterations in healthy postmenopausal women.

Authors:  R Rizzoli; A Sigaud; M Azria; F R Herrmann
Journal:  Osteoporos Int       Date:  2014-10-22       Impact factor: 4.507

Review 7.  Individualizing osteoporosis therapy.

Authors:  S Silverman; C Christiansen
Journal:  Osteoporos Int       Date:  2012-01-05       Impact factor: 4.507

8.  Intra-articular delivery of a nanocomplex comprising salmon calcitonin, hyaluronic acid, and chitosan using an equine model of joint inflammation.

Authors:  Svenja Sladek; Clodagh Kearney; Daniel Crean; Pieter A J Brama; Lidia Tajber; Karolina Fawcett; Margot C Labberte; Bernadette Leggett; David J Brayden
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

9.  Calcitonin and Amylin Receptor Peptide Interaction Mechanisms: INSIGHTS INTO PEPTIDE-BINDING MODES AND ALLOSTERIC MODULATION OF THE CALCITONIN RECEPTOR BY RECEPTOR ACTIVITY-MODIFYING PROTEINS.

Authors:  Sang-Min Lee; Debbie L Hay; Augen A Pioszak
Journal:  J Biol Chem       Date:  2016-02-19       Impact factor: 5.157

Review 10.  Calcitonin for treating acute and chronic pain of recent and remote osteoporotic vertebral compression fractures: a systematic review and meta-analysis.

Authors:  J A Knopp-Sihota; C V Newburn-Cook; J Homik; G G Cummings; D Voaklander
Journal:  Osteoporos Int       Date:  2011-06-10       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.